Full Text View
Tabular View
No Study Results Posted
Related Studies
Vertebroplasty for the Treatment of Fractures Due to Osteoporosis
This study has been completed.

First Received on September 10, 2003.   Last Updated on August 23, 2011   History of Changes
Sponsor: Mayo Clinic
Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by: Mayo Clinic
ClinicalTrials.gov Identifier: NCT00068822
  Purpose

Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.


Condition Intervention Phase
Spinal Fractures
Osteoporosis
Device: Percutaneous vertebroplasty
Procedure: Placebo
Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Back-specific functional status using Roland Scale at the 1-month time frame [ Time Frame: Month 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Health status outcome using SF-36 [ Time Frame: Month 1 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 294
Study Start Date: April 2003
Study Completion Date: September 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will receive percutaneous vertebroplasty
Device: Percutaneous vertebroplasty
Placement of PMMA into vertebral compression fracture
Placebo Comparator: 2
Participants will receive partial vertebroplasty without PMMA
Procedure: Placebo
Placebo surgery

Detailed Description:

Spontaneous, atraumatic compression fractures due to osteoporosis occur in more than 700,000 patients per year. Pain associated with these fractures may be excruciating, but before the advent of percutaneous vertebroplasty, treatment options were limited. Analgesic medications, bed rest, and bracing have been the mainstays of treatment, but each of these therapies has substantial limitations.

Because of the dearth of viable treatment options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have not accounted for numerous important potential biases, including the natural tendency for compression fractures to heal spontaneously, regression toward the mean (wherein patients seek medical attention when pain is maximum), and the placebo effect. This study will examine the clinical efficacy of percutaneous vertebroplasty for treatment of painful osteoporotic vertebral compression fractures.

Participants in this study will be randomly assigned to receive either percutaneous vertebroplasty or a sham procedure (placebo control group). Participants may have up to 2 spinal levels treated. Participants will be enrolled in the study for 1 year and will have study visits at entry and Months 1 and 12. There will also be phone visits at Days 1, 2, 3, and 14 and Months 3 and 6. After Month 1, crossover from the placebo group to the vertebroplasty group will be allowed.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed osteoporosis or osteopenia
  • Vertebral compression fracture in vertebrae T4 through L5
  • Pain not responsive to medical therapy

Exclusion Criteria:

  • Malignant tumor or spinal canal compromise
  • Local or systemic infection
  • Pregnancy
  • Hip fracture
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068822

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: David F. Kallmes, MD Mayo Clinic
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David F. Kallmes, MD (PI), Mayo Clinic
ClinicalTrials.gov Identifier: NCT00068822     History of Changes
Other Study ID Numbers: 1912-03, R01AR049373, NIAMS-096
Study First Received: September 10, 2003
Last Updated: August 23, 2011
Health Authority: United States: Federal Government

Keywords provided by Mayo Clinic:
Vertebroplasty
Crushed Vertebrae
Back Pain
Structurally Unstable Vertebrae

Additional relevant MeSH terms:
Fractures, Bone
Osteoporosis
Spinal Fractures
Osteoporotic Fractures
Wounds and Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Spinal Injuries
Back Injuries

ClinicalTrials.gov processed this record on February 09, 2012